WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on 18 March 2025. The Chinese contract research, development, and ...
With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. | With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the ...
China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
WuXi AppTec (OTCPK:WUXIF) has agreed to sell the U.S. and U.K.-based operations of its WuXi Advanced Therapies unit, which ...
Hosted on MSN3mon
WuXi AppTec Offloads Gene Therapy Unit Amid Rising US RestrictionsWuXi AppTec, a prominent Chinese company listed on the Shanghai Stock Exchange, has announced the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, to U.S.-based ...
The Biotechnology Innovation Organization (BIO) has said it is parting company with Wuxi AppTec, while voicing support for US legislation that would block Chinese biotechs from federal funding and ...
Shares in WuXi AppTec rose sharply after the Chinese biotechnology company proposed a special dividend and share buyback following weaker annual results. The company's shares in Hong Kong climbed ...
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States. As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback